ValuEngine upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a hold rating to a buy rating in a research report sent to investors on Saturday.

Several other brokerages also recently weighed in on INO. Maxim Group restated a buy rating and set a $8.00 target price on shares of Inovio Pharmaceuticals in a research note on Thursday, August 16th. BidaskClub downgraded Inovio Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, July 27th. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, August 7th. Finally, Stifel Nicolaus initiated coverage on Inovio Pharmaceuticals in a research note on Tuesday, October 2nd. They set a buy rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $10.75.

Shares of INO stock opened at $4.84 on Friday. Inovio Pharmaceuticals has a 1-year low of $3.64 and a 1-year high of $6.30. The firm has a market cap of $484.02 million, a P/E ratio of -4.46 and a beta of 1.88.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. Inovio Pharmaceuticals had a negative return on equity of 72.66% and a negative net margin of 232.58%. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $2.20 million. During the same period in the previous year, the business earned ($0.39) EPS. As a group, analysts predict that Inovio Pharmaceuticals will post -1.06 earnings per share for the current year.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim sold 49,060 shares of the business’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $5.37, for a total transaction of $263,452.20. Following the sale, the chief executive officer now owns 2,357,554 shares in the company, valued at approximately $12,660,064.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.40% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Wellington Shields Capital Management LLC purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter worth about $170,000. Levin Capital Strategies L.P. boosted its stake in shares of Inovio Pharmaceuticals by 80.5% in the second quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 16,500 shares during the last quarter. Wellington Shields & Co. LLC purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter worth about $267,000. Emerald Advisers Inc. PA purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter worth about $228,000. Finally, ING Groep NV purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter worth about $389,000. Institutional investors and hedge funds own 31.87% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Featured Article: What is Cost of Capital?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.